Pharmacological preconditioning of ischemic heart disease by low-dose dipyridamole
- 30 September 1996
- journal article
- Published by Elsevier in International Journal of Cardiology
- Vol. 56 (1) , 17-27
- https://doi.org/10.1016/0167-5273(96)02712-x
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Prodromal Angina Limits Infarct SizeCirculation, 1995
- Adenosine and Dipyridamole Mimic the Effects of Ischemic PreconditioningJournal of Molecular and Cellular Cardiology, 1994
- The Anti-infarct Effect of an Adenosine A1-Selective Agonist is Diminished After Prolonged Infusion as is the Cardioprotective Effect of Ischaemic Preconditioning in Rabbit HeartJournal of Molecular and Cellular Cardiology, 1994
- Preconditioning the human myocardiumThe Lancet, 1993
- Dipyridamole potentiates the myocardial infarct size-limiting effect of ischemic preconditioning.Circulation, 1992
- Ischaemic preconditioning: from mechanisms to exploitationCardiovascular Research, 1992
- Intravenous pretreatment with A1-selective adenosine analogues protects the heart against infarction.Circulation, 1992
- Protection against infarction afforded by preconditioning is mediated by A1 adenosine receptors in rabbit heart.Circulation, 1991
- Adaptation to ischemia during percutaneous transluminal coronary angioplasty. Clinical, hemodynamic, and metabolic features.Circulation, 1990
- Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium.Circulation, 1986